OnKure Therapeutics, Inc.
OKUR Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$2.48
KIRA · Stoqly’s AI analyst, in plain words
- OnKure Therapeutics, Inc. had $3.4M of revenue in fiscal 2025.
- Its operating margin was −1,833.7%: of every 100 in sales, about −1,834 is left after running the business.
- OnKure Therapeutics, Inc. lost $59.5M in fiscal 2025.
- Free cash flow was −$51.9M in fiscal 2025, −1,511.0% of revenue.
Market cap
$123M
P/E
—
Revenue
$3.4M
Net income
−$59.5M
Free cash flow
−$51.9M
Operating margin
−1,833.7%
OnKure Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−1,733.7%
No. It lost money last year.
Does profit turn into cash?
−1,511.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What OnKure Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- OnKure Therapeutics, Inc.
- CIK
- 0001637715
OnKure Therapeutics, Inc. · OKUR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | $1.6M | $0.0M | $3.4M |
| Revenue growth | — | — | — | −100.0% | — |
| Net interest income | — | — | $1.6M | $1.7M | $3.4M |
| Operating margin | — | — | −2,275.7% | — | −1,833.7% |
| Net income | −$39.8M | −$52.0M | −$35.3M | −$52.7M | −$59.5M |
| Net margin | — | — | −2,175.7% | — | −1,733.7% |
| Diluted EPS | −$2.19 | −$2.12 | −$124.41 | −$15.28 | −$4.40 |
| Cash | |||||
| Cash from operations | −$38.0M | −$47.4M | −$34.5M | −$51.1M | −$51.8M |
| Capital expenditure | $0.2M | $0.3M | $0.2M | $0.1M | $0.0M |
| Free cash flow | −$38.2M | −$47.7M | −$34.8M | −$51.2M | −$51.9M |
| FCF margin | — | — | −2,143.7% | — | −1,511.0% |
| Share buybacks | — | — | $4.4M | — | — |
| Share count change | 794.6% | 35.0% | −98.8% | 1,114.6% | 292.1% |
| Debt and strength | |||||
| Cash and short-term investments | $148M | $101M | $105M | $111M | $59.1M |
| Shareholders' equity | $147M | −$54.4M | −$102M | $104M | $56.2M |
| Current ratio | 24.8x | 14.9x | 4.6x | 10.7x | 10.3x |
| Returns and quality | |||||
| Return on equity | −75.7% | −112.0% | — | −5,304.4% | −74.4% |
| Return on tangible equity | −27.0% | — | — | −50.7% | −105.9% |
| Piotroski F-score | — | — | — | 3 | 2 |
| Altman Z'' | 25.4 | −8.4 | −25.2 | 8.1 | −2.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
OnKure Therapeutics, Inc. · OKUR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.48 a share, the company is worth $123M.
Source: SEC EDGAR XBRL filings (CIK 0001637715). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.